Drugmaker Bayer has filed an appeal against an Indian Patents Office’s order, which allowed domestic drug maker Natco Pharma to sell a generic version of the German firm’s cancer drug ‘Nexavar’ in India, with the Intellectual Property Appellate Board. In March this year, India had invoked a law permitting Hyderabad-based Natco Pharma to manufacture and sell cancer-treatment drug Nexavar at a price over 30 times lower than charged by its patent-holder Bayer Corporation. “We strongly disagree with the conclusions of the Patent Controller of India and have appealed his order on May 4, 2012 with the Intellectual Property Appellate Board,” a Bayer Spokesperson said in a statement.
